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Abstract: There has been a considerable advancement in the treatment of diabetes and 
understanding of the biochemical mechanisms underlying diabetic complications in the last 
20 years. However, this advancement has not translated into a consistent reduction in diabetic 
retinopathy, one of the most frightening complications of diabetes mellitus. It is probable that 
greater attention to preventive intervention will help reduce the damage load in the next future, 
and that several drugs for the treatment of more advanced stages of diabetic retinopathy will 
become available. Competent strategies targeting prevention based on screening programs 
should be proposed to reduce the burden and to improve the clinical outcome of this   devastating 
diabetes complication.
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Epidemiology
Although there have been advancements in the treatment of diabetes in recent years, 
diabetic retinopathy (DR) remains the most common cause of blindness among adults. 
According to the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), 
3.6% of type 1 diabetes patients and 1.6% of type 2 diabetes patients were legally 
blind.1 The time of disease onset is evident in type 1 diabetes patients, therefore we 
know with certainty that the development of DR is unusual before the fifth year of 
disease onset and reaches a prevalence of more than 95% 15 years after disease onset. 
On the contrary, up to 20% of type 2 diabetes mellitus patients, in whom the exact 
time of onset of the disease is less evident, may have signs of retinopathy at the time 
of diagnosis, which in most cases is preceded by a long unrecognized latency period. 
The prevalence of DR 15 years after disease onset in type 2 diabetes mellitus patients 
may reach 60%.2 The UK Prospective Diabetes Study (UKPDS), a 10-year study of 
newly diagnosed type 2 diabetes patients, indicates that the presence of even a single 
aneurysm in these patients is evidence of DR, with the prevalence of this condition 
at diagnosis being 38%.2 Although the percentage is higher among type 1 diabetes 
patients, the much greater absolute number of type 2 diabetes patients with this disease 
indicates DR to be a devastating complication in this category.3
However, the prevalence of progressive sight-threatening retinopathy is limited 
to 10%,4 which is still relatively high. The prevalence of DR of any severity in the 
diabetic population as a whole is approximately 30%.5 Furthermore, we cannot 
  accurately predict when severe DR will progress to blindness, although hyperglycemia 
and hypertension are risk factors. The actual prevalence of blindness is approximately 
5% (range 3%–7%) and may be as high as 8%.4Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Although there are no comparative studies, it is highly 
probable that the incidence of diabetes mellitus in all its forms 
may vary according to the local resources and   standards 
of care. There is abundant literature demonstrating that 
  screening programs have been highly effective in reducing 
the incidence and the progression of DR.6
Etiology and pathogenesis
Diabetic retinopathy tends to follow a progressive course 
from minor lesions to the most serious sight-threatening 
patterns, but there is frequently considerable overlapping. 
The earliest manifestations are mild and characterized by 
increased vascular permeability, followed by moderate to 
severe changes with intravascular clotting, defined as non-
proliferative DR. A more advanced phase is the proliferation 
of new vessels, defined as proliferative DR (PDR), with 
impending risk of hemorrhage. An ominous manifestation 
is significant macular edema (clinically significant diabetic 
macular edema [CSDME]) caused by retinal thickening due 
to leaky blood vessels, which should be distinguished from 
mild thickness of the retina that does not have the same 
serious prognosis. This sight-threatening complication may 
supervene at any stage of the DR.
The earliest changes are a loss of retinal neurons (neu-
rodegeneration) and disruption of the vascular structure, 
which is essential to the survival of the retina.7 Interruption 
of the integrity of retinal capillary bed, which allows the 
exchange of nutrients with the retina, leads to protein leakage 
and the appearance of exudates, which are among the early 
signs of DR. It is highly probable that the hyperglycemia 
in   diabetes leads to an array of metabolic changes, many 
of which may be directed toward limitation or repair of the 
damage. Unfortunately this hypothesis has not yet been 
accepted. All the above factors and possibly some other 
unknown factors interact to cause DR, and it is not known 
yet which factor may be the primary cause.
The most well known structural components of   retinal 
capillaries are the basement membrane and pericytes, which 
are cells that have both structural and regulatory functions.8 
The disarrangement of these structures leads to weakening 
of the capillaries, aneurism, and protein   leakage. Loss of 
retinal pericytes is an early feature of DR and correlates 
with microaneurysm.9 Other common features of early DR 
are the   thickening of the capillary basement   membrane 
and the increased deposition of extracellular matrix 
  components, leading to the development of abnormal retinal 
  hemodynamics.10 A subsequent intervention of blood cells 
that clog the capillaries and lead to occlusion is probably 
the body’s misguided attempt at damage limitation.11 There 
is extensive clot formation in the capillaries as the disease 
progresses, which interrupts blood flow and causes ischemia. 
In more advanced stages, there is an inordinate proliferation 
of blood vessels in an attempt to restore oxygen and   nutrient 
supply to the ischemic territory. Pathogenesis of PDR is 
essentially due to ischemia, and pathogenesis of CSDME is 
due to the fluid leakage from retinal blood vessels into the 
area of the macula, which is rich in cones that are critical 
for color and daytime vision. This study mainly reviews 
prevention in the initial stages of the disease when medical 
intervention may be effective. Proliferation may be mediated 
by vascular endothelial growth factor (VEGF), which will 
be discussed later.
The etiology of DR is complex and predisposing factors 
are as follows: 1) duration of diabetes,12 2) poor glucose 
control,13 3) hypertension,14,15 4) pregnancy,16,17 5) puberty,18 
6) renal disease19 (the relation between kidney and retina is 
so relevant that the diagnosis of diabetic nephropathy should 
always be questioned in the absence of a DR), and 7) hyper-
lipidemia20 (believed to play a role in this complication, 
although this hypothesis has not been confirmed).21 These 
factors will be discussed in detail.
The pathogenesis of DR includes both systemic and local 
factors, but we still do not know the exact influence of and 
role played by each in the different stages of the disease.
Duration of diabetes
The duration of diabetes is probably the strongest predictor 
of progression to DR,6 but is not clinically helpful in most 
cases of type 2 diabetes because diagnosis is delayed and 
the time of onset of the disease is unknown. The WESDR 
showed that incidence of retinopathy increased progressively 
from 8% 5 years after disease onset to 80% after 15 years.22 
The recognition of the role of disease duration is one more 
argument in favor of those interventions that may delay the 
onset of diabetes. After disease onset nothing can be done 
to reduce this risk factor.
Hyperglycemia
The role of hyperglycemia was proven by two landmark 
  studies. The Diabetes Control and Complications Trial 
(DCCT), a study of 1441 type 1 diabetes patients randomly 
assigned to intensive and conventional treatment groups 
with different glycosylated hemoglobin (HbA1c) levels, 
  conclusively demonstrated that good control plays a critical 
role in the prevention of DR. In the intensively treated group, 
there was a reduction of 76% in the risk of progression. Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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The patients were assigned to a primary prevention group 
(those with no signs of retinopathy) and a secondary preven-
tion group (those with retinopathy) according to the status 
of their retina. Those in the primary prevention cohort had a 
similar cumulative incidence of retinopathy progression in the 
conventional and intensive arms untill 36 months, and then 
intensive treatment reduced the risk of retinopathy by 76%. 
The intensive group in the secondary intervention cohort fared 
worse than the nonintensive group during the first 18 months; 
a phenomenon largely offset by a much greater long-term 
improvement with a reduced risk of 54% by 36 months.13 
The results of the Epidemiology of Diabetes Interventions 
and Complications study, a follow-up study to the DCCT, are 
interesting from a theoretical perspective because there was 
no further attempt to use intensive treatment and the HbA1c 
levels of the two groups were nearly the same. Even after 
5 years, outcome of the intensive therapy was favorable.23 
This phenomenon is termed a ‘legacy effect’. The data were 
deemed so relevant that, subsequently, the level of fasting 
blood glucose at which retinopathy appeared was included in 
the current criteria for the diagnosis of diabetes mellitus. In a 
recent study on the association of glycated HbA1c and fasting 
plasma glucose (FPG) with the diagnosis of diabetes mellitus, 
the authors found that the highest increase in the prevalence 
of retinopathy occurs among individuals with HbA1c $ 5.5 
and FPG $ 5.8 mmol/L, and that, based on the areas under 
the receiver operating characteristic curves, HbA1c was found 
to be a strong discriminator of retinopathy.24
With a protocol similar to that of the DCCT, the UKPDS 
randomly assigned 3867 newly diagnosed type 2 diabetes 
patients to an intensive or conventional treatment group and 
found a statistically significant 25% reduction in microvas-
cular complications including the need for photocoagulation 
of the retina. This is a much more crude result than in the 
DCCT because the impact on each complication was not 
clearly determined and favored lowering blood glucose 
levels. An epidemiological analysis of the UKPDS data 
demonstrated the existence of a continuous relationship 
between the risk of microvascular complications and blood 
glucose level; for each percentage point decrease in HbA1c, 
the relative risk of microvascular complication was reduced 
by 35%.25 A follow-up of the UKPDS subjects, analogous to 
that of the DCCT, demonstrated the existence of the legacy 
effect, with a 24% reduction in the risk of microvascular 
complications.26
The Veterans Affairs Diabetes Trial (VADT) that 
  followed a different population of 1791 older diabetic 
  veterans, mostly men, for a median of 5.6 years did not find 
any effect from intensive glucose control on   retinopathy 
(progression to proliferative disease, macular edema, 
increase in severity of disease, and new onset of disease; 
all P = not specified [NS]).27 Similar results were obtained 
for the ADVANCE (Action in Diabetes and Vascular Dis-
ease: Preterax and Diamicron MR Controlled Evaluation) 
study in which there were no changes in the rate of severe 
retinopathy.28 Taken together, these observations suggest 
that the effect of good glycemic control is most evident at 
disease onset when harmful microvascular complications 
can set in. Any later intervention is likely to have only 
modest beneficial effect. This is confirmed by the UKPDS 
observation that a favorable legacy effect of glucose control 
was found in newly diagnosed subjects which lasted until 
follow-up.26 However, the VADT and ADVANCE studies 
in a longstanding diabetic population did not find any 
significant effect.
The exact mechanisms that cause persistent hyperglyce-
mia to become DR are still partially unknown, however, the 
polyol pathway has been found to play a prominent role.28 
The polyol pathway is dependent on the glucose overload to 
the noninsulin-dependent cells such as cells of the eye.29 This 
pathway leads to the intracellular accumulation of sorbitol 
and fructose.30 It has been demonstrated that the increase in 
aldose reductase activity within the retinal cells contributes 
to oxidative stress and overexpression of VEGF protein.31 
Furthermore, an increased frequency of the Z-2 allele of 
the aldose reductase gene in diabetes patients with DR vs 
those without DR (39.1% vs 26.5%; χ2 = 6.9) has been 
  demonstrated, which partially explains the role of genetics in 
this complication.31,32 Modest results were obtained in thera-
peutic trials with aldose reductase inhibitors that reduce the 
efficiency of the polyol pathway, and one of these substances 
purported to be beneficial for diabetic neuropathy has now 
been withdrawn from the market for proven negative cost-to-
benefit ratio.33,34 Furthermore, these drugs have frequent and 
potential dangerous side effects (liver and kidney damage).
Increased oxidative stress causes a characteristic 
endothelial dysfunction, which has been observed in diabetes 
patients and normal subjects.35,36 Brownlee and colleagues 
demonstrated that damage can be reversed by suppression 
of intracellular free radicals with manganese superoxide 
dismutase, which has an antioxidant effect.37 Another impor-
tant and still not totally explored aspect is that oxygen-free 
radicals can activate nuclear factor κB and in turn many 
genes related to vascular stress response.38 One disappointing 
aspect is that clinical trials with vitamin E, a potent antioxi-
dant, failed to demonstrate beneficial effects.39 This failure Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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could be explained by the fact that since vitamin E only acts 
by   scavenging already formed oxidants in this antioxidant 
therapy, this therapy may be a more “symptomatic” rather 
than causal treatment for vascular oxidative stress.40
The formation of advanced glycation end products 
(AGEs) may also have a role. These compounds result from 
the nonenzymatic binding of glucose to protein side chains.41 
Accumulation of these protein side chains in the capillaries 
of the retina leads to loss of pericytes, causing blood–retinal 
barrier dysfunction, increasing synthesis of VEGF in the 
retina,42 and increasing monocyte adhesion to the retinal 
endothelial cells through an increase in the expression of 
intercellular adhesion molecule 1.43 Aminoguanidine, an 
inhibitor of AGE formation, appears to reduce the early 
histological changes in the retina. However, the drug causes 
anemia in humans.44
Another mechanism of damage is the activation of the 
protein kinase C (PKC) family pathway.45 This pathway is a 
consequence of hyperglycemia and has a role in the patho-
genesis of DR.46 The main isoform implicated is PKC-β2, 
which causes hyperexpression of endothelin, increased 
vascular permeability, alterations in renal blood flow, and 
in vitro stimulations of VEGF secretion.47 Two drugs with 
  inhibitory effect have been developed, ruboxistaurin (Eli Lilly, 
Indianapolis, IN) and midostaurin, but their effectiveness is 
still uncertain.48 Brownlee recently put forth a unifying theory 
according to which glucose overload flowing through the 
glycolytic pathway could cause a kind of “collateral damage” 
consisting of superoxide production in endothelial cells at 
the mitochondrial level. The superoxide could cause DNA 
damage in turn, and the consequent attempt to repair the 
damage could start the aforementioned dangerous cascades 
involved in diabetes complications.49 The existence of all 
these pathways leading to diabetic complications led to the 
search for antioxidant compounds that are still in the pipe-
line or in early experimental stages. Among the available 
compounds, lipoic acid is purported to have the ability to 
restore endothelial function in diabetes.50 As will be dealt with 
later, other commonly used drugs such as thiazolidinediones, 
  statins, angiotensin-converting enzyme inhibitors (ACEI), 
and angiotensin type 1 (AT1) receptor blockers may also 
have potent antioxidant effects, although there are no evident 
conclusive results for the protection of the retina.
An increase in VEGF, a family of proteins mitogenic for 
vascular endothelial cells that increase vascular permeability, 
has been demonstrated in DR.51 The knowledge of the role 
of these substances led to extensive research on its antago-
nists. The systemic administration of these antagonists might 
cause serious damage by blocking angiogenesis, impairing 
the response to ischemic events, worsening peripheral isch-
emia, increasing proteinuria, and impairing wound healing 
process,52 and hence the use of these agents is restricted to 
intravitreal administration. However, a backflow is   possible 
from the vitreal chamber to the systemic circulation.53 
It has yet to be proven that these agents for intravitreal 
  administration are preferred over triamcinolone acetonide.
Other growth factors of interest are growth hormone 
(GH) and insulin-like growth factor-1 (IGF-1). Hypophy-
sectomy was performed in advanced DR in the past,54 with 
a good rate of regression. Further evidence for the role of 
GH or IGF-I comes from the observation of the increased 
rate of appearance and progression of the DR in puberty and 
pregnancy, which are stages of increased GH secretion.55 
The GH antagonist, pegvisomant, has been used to induce 
regression of neovascularization, with a negative outcome.56 
Octreotide, a somatostatin analog, decreases the need for 
photocoagulation.57
Although the literature on the pathogenetic mechanisms 
that lead to DR is abundant, exploiting the mechanisms did 
not yield fruitful results. Control of hyperglycemia proved 
to be the mainstay of prevention of DR and progression 
of the disease was able to be reversed to a certain point. 
In the intensive treatment of diabetes, the physicians should 
make any effort to avoid the risk of hypoglycemia as it is 
a risk factor for progression to DR. The Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) eye study,58 a 
subset of the ACCORD trial, was designed primarily to study 
the effects of intensive glycemic control on cardiovascular 
events in type 2 diabetes subjects. The primary outcome of 
2,856 subjects was a 3-step change on a 17-step retinopathy 
scale (from retinal photographs) or development of PDR. 
After 4 years of follow-up, intensive treatment to lower the 
blood glucose to normal levels significantly reduced the 
incidence of progressive DR compared with conventional 
treatment that resulted in a higher HbA1c levels (7.3% vs 
10.2%), but not vision loss (16.3% vs 16.7%). However, 
the drawbacks of this study were the excess mortality and 
the absence of positive effects on adverse cardiovascular 
events in the intensive arm. Although the exact cause of the 
increased mortality is not known, there is general agreement 
that the intensive intervention to reduce the blood glucose 
level should be individually weighed against the risk.
We observed an unexpected improvement in the most 
initial forms of retinopathy while using a combination of 
arginine, glutamine, and hydroxy-β-butyrate coupled with 
an increased percentage of dietary protein for the treatment Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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of diabetic foot ulcers over 14 months. This combination 
treatment can increase the formation of collagen fibers. 
The treated patients presented a reduction in the number 
of microaneurysms after 6 months (20%; P = 0.012) and 
12 months (39%; P = 0.006), and retinal exudates were 
reduced 38.6% (P = 0.000) at 6 months and 52% at 12 months 
(P = 0.003). We hypothesize that protein loss in diabetes 
patients through neoglycogenesis and proteinuria may cause 
a disarrangement of the basement membrane of the retinal 
capillaries, a phenomenon that was reversed by diet and the 
combination of drugs.
Blood pressure
There is sufficient data to validate high blood pressure as a 
risk factor for DR and the positive effect of blood pressure 
reduction on the progression of the disease.59 The UKPDS 
showed that intensive blood pressure control in type 2 diabetes 
was effective in reducing the microvascular   complication 
associated with diabetes. Analogous to the results of blood 
glucose control, the initial study results released in 1997 
demonstrated that an effective blood pressure control could 
induce a relative risk reduction of 37%.60
However, contrary to the blood glucose results, there was 
no legacy effect for blood pressure and the UKPDS follow-up 
study in 2007, 10 years after the intensive treatment had 
been interrupted, reported only 16% relative risk reduction 
in the intensive group (P = NS). Thus, it appears that good 
blood pressure control must be continued to control disease 
progression.61
The ACCORD eye study group published the results of 
the effects at 4 years of either intensive or standard treatment 
for diabetes and dyslipidemia or for systolic blood pressure 
control on 2856 diabetes subjects.58 In 4 years, the rate of pro-
gression was 10.4% with intensive blood pressure lowering 
treatment vs 8.8% with standard therapy (P = NS).   According 
to the authors, intensive glycemic control and intensive com-
bination treatment of dyslipidemia, but not intensive pressure 
control, reduced the rate of progression of DR.
There have been many studies on ACEI and angiotensin 
receptor blockers (ARBs) to investigate the existence of direct 
effects not mediated by blood pressure reduction. The basis 
for these studies is the discovery of the renin–angiotensin 
system in the eye62 and the in vitro binding of angiotensin 
II to the AT1 receptors, which causes a series of negative 
effects such as inflammation, oxidative stress, neoangio-
genesis, and fibrosis.63 However, the in vivo studies did not 
confirm these observations completely. The UKPDS did not 
find any significant differences among patients treated with 
atenolol, a beta blocker, and those treated with   captopril, an 
ACEI.   However, captopril is a very old drug with a short 
half-life. The EUCLID study did not consider DR as a 
  primary end-point and demonstrated that normoalbuminuric 
and microalbuminuric lisinopril could significantly reduce 
the progression of DR in normotensive diabetes patients 
but with no decrease in incidence.63 However, in this study, 
statistical significance almost disappeared after adjusting 
for the mean HbA1c of the control group. Furthermore, the 
follow-up period was only 2 years. Thus, this study can be 
considered only suggestive and not conclusive. In another 
highly sophisticated study, the Direct Protect, in which both 
type 1 and 2 diabetes patients were studied for prevention 
and progression of DR with the ARB candesartan, the only 
clearly significant outcome not specified as a primary end-
point was a 34% regression (P = 0.009) mostly in subjects 
with mild disease.64 Overall, one can surmise that the benefits 
attributable to the current ACEI/ARB blockers are marginal 
or absent.
The current recommendations for control of blood glucose 
and hypertension are HbA1c , 7% (,6.5% according to the 
European Association for the Study of Diabetes) and blood 
pressure #130/80 mm Hg.65
Dyslipidemia
Among the known risk factors, hyperlipidemia is associated 
with the presence of hard exudates in the retina,66 which has 
been confirmed by recent studies. Nathan and colleagus found 
a significant association of total to high-density lipoprotein 
(HDL) cholesterol ratio and triglycerides only on significant 
macular edema and hard exudates, which in itself is not proof 
of cause–effect.67 The Fenofibrate Intervention and Event 
Lowering in Diabetes study was designed to answer these 
questions. Fenofibrate is a peroxisome proliferator receptor 
(PPR)-α agonist that lowers triglycerides, reduces total and 
low-density lipoprotein (LDL) cholesterol, increases HDL 
cholesterol, and decreases small LDL particles and apolipo-
protein B.67 Fenofibrate reduced the need for laser treatment 
and less consistently the progression of retinopathy.68 The 
effects of fenofibrate are independent of lipid levels, as 
demonstrated by the observation that PPR-α may reduce the 
expression of VEGF receptor 2.69
Although the aim of this review is limited to the phar-
macological treatment of DR, it is worth mentioning that 
most of the effective treatments of DR now involve surgi-
cal or laser procedures. Vitrectomy laser treatments have 
effectively revolutionized prognosis, although there are still 
drawbacks.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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The correct therapeutic approach to DR can be 
  summarized as follows: blood glucose control; fundus 
  examination (  ophthalmoscopy, retinal fluoroangiography, 
indocyanine green angiography, and optical coherence 
tomography); evaluation of the stage of progression if any; 
retinal laser therapy to prevent the proliferation of neoves-
sels; or surgical therapy in growth of neovessels into the 
  vitreous, in vitreous hemorrhage, or in fibrous tissue pro-
liferation on the retinal surface or on the optical disc. In 
these cases, vitrectomy is the only methodology available to 
interrupt the progression of the disease, through the suction 
of hematic vitreous, that, if left untreated, is an obstacle to 
vision and supports the growth of neovessels.
Furthermore, the intravitreal injection of anti-VEGF drugs 
(ranibizumab, pegaptanib, bevacizumab, etc) improved the 
prognosis of retinal neovessels and exudative disorders.
All these observations are complicated because DR is 
probably not a single disease, and the dependency on different 
causative factors may vary according to the different stages of 
the disease. Clinicians may be disappointed by divergent and 
often conflicting study results if the studies do not consider 
this aspect of the disease. Furthermore, some drugs used 
to reduce the blood glucose may damage the retina. One 
example is the use of rosiglitazone, suspected of causing 
macular edema under certain circumstances,69 although we 
did not find any effect in a retrospective series.70
Conclusion
Current medical interventions may be useful if carried out 
early, and the effect is limited to the rate of appearance and 
the minor manifestations of the disease. When the disease 
progresses, the best treatment option is laser therapy or 
surgery, and is not the recommended medical treatment at 
present.
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